• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促甲状腺激素受体在甲状腺乳头状癌亚型中的表达及临床意义

Expression and Clinical Significance of Thyroid-stimulating hormone receptor in the Subtypes of Papillary thyroid carcinomas.

作者信息

Shen Wei, Zhang Shanshan, Li Qinghuai

机构信息

Wei Shen, Department of Thyroid and Breast Surgery, The Second Hospital of Hebei Medical University, 215 Peace West Road, Shijiazhuang 050000, Hebei, P.R. China.

Shanshan Zhang, Department of Thyroid and Breast Surgery, The Second Hospital of Hebei Medical University, 215 Peace West Road, Shijiazhuang 050000, Hebei, P.R. China.

出版信息

Pak J Med Sci. 2023 Jan-Feb;39(1):198-202. doi: 10.12669/pjms.39.1.6096.

DOI:10.12669/pjms.39.1.6096
PMID:36694763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9842975/
Abstract

OBJECTIVE

To investigate the expression of TSH receptors (TSHR) in various subtypes of Papillary thyroid carcinomas (PTC) by immunohistochemistry.

METHODS

Retrospective analyses were carried out to the clinical data of 108 PTC patients randomly admitted into the Department of Thyroidthyroid surgery thyroid surgery and Breast Surgery, The Second Hospital of Hebei Medical University from March 2020 to December 2020. The archived paraffin blocks of the 108 cases as well as 18 contiguous normal thyroid tissues (control group) were taken from the Department of Pathology of The Second Hospital of Hebei Medical University. The pathological types of all PTC tissues were detected and the expression of TSHR was determined.

RESULTS

TSHR expression was 86.11% positive in PTC tissues; with 85.00% positive in classical group; with 75.86% positive in micro group; with 84.61% positive in follicular group; with 83.33% positive in oncocytic group; with 50.00% positive in invasive group. TSHR expression was 100% in normal thyroid tissues. So TSHR expression in normal thyroid tissues is significantly higher than that in PTC; TSHR expression in microcarcinoma is stronger than in the other subtypes; there is no significant difference among the other subtypes.

CONCLUSIONS

TSH suppression works better on microcarcinoma than on the other subtypes. And the effects on non-invasive subtypes are better than on invasive subtypes.

摘要

目的

采用免疫组织化学方法研究促甲状腺激素受体(TSHR)在甲状腺乳头状癌(PTC)各亚型中的表达情况。

方法

回顾性分析2020年3月至2020年12月随机入住河北医科大学第二医院甲状腺乳腺外科的108例PTC患者的临床资料。这108例病例的存档石蜡块以及18例相邻正常甲状腺组织(对照组)取自河北医科大学第二医院病理科。检测所有PTC组织的病理类型并测定TSHR的表达。

结果

PTC组织中TSHR表达阳性率为86.11%;经典型组阳性率为85.00%;微小癌组阳性率为75.86%;滤泡型组阳性率为84.61%;嗜酸细胞型组阳性率为83.33%;浸润型组阳性率为50.00%。正常甲状腺组织中TSHR表达为100%。所以正常甲状腺组织中TSHR表达显著高于PTC;微小癌中TSHR表达强于其他亚型;其他亚型之间无显著差异。

结论

促甲状腺激素抑制对微小癌的效果优于其他亚型。对非浸润性亚型的效果优于浸润性亚型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b965/9842975/064192820cec/PJMS-39-198-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b965/9842975/3d740ee28486/PJMS-39-198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b965/9842975/064192820cec/PJMS-39-198-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b965/9842975/3d740ee28486/PJMS-39-198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b965/9842975/064192820cec/PJMS-39-198-g002.jpg

相似文献

1
Expression and Clinical Significance of Thyroid-stimulating hormone receptor in the Subtypes of Papillary thyroid carcinomas.促甲状腺激素受体在甲状腺乳头状癌亚型中的表达及临床意义
Pak J Med Sci. 2023 Jan-Feb;39(1):198-202. doi: 10.12669/pjms.39.1.6096.
2
Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.促甲状腺激素受体影响甲状腺乳头状癌的转移和预后。
Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3582-91.
3
Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.钠/碘同向转运体和促甲状腺激素受体在人甲状腺癌中的表达及相关性
Tumori. 2011 Jul-Aug;97(4):540-6. doi: 10.1177/030089161109700420.
4
Expression of sodium/iodide transporters and thyroid stimulating hormone receptors in thyroid cancer patients and its correlation with iodine nutrition status and pathology.甲状腺癌患者中钠/碘转运体和促甲状腺激素受体的表达及其与碘营养状况和病理的关系。
Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4573-4580. doi: 10.26355/eurrev_201807_15513.
5
CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA.循环甲状腺刺激激素受体信使核糖核酸作为甲状腺微小乳头状癌患者肿瘤侵袭性的标志物
Endocr Pract. 2015 Jul;21(7):777-81. doi: 10.4158/EP14425.OR. Epub 2015 Mar 18.
6
Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment.促胃液素抑制素受体 2 和促甲状腺激素受体在嗜酸细胞性甲状腺肿瘤中的表达:对预后和治疗的影响。
Mod Pathol. 2023 Dec;36(12):100332. doi: 10.1016/j.modpat.2023.100332. Epub 2023 Sep 15.
7
Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients.甲状腺乳头状癌患者外周血中促甲状腺激素受体mRNA表达水平与不良临床病理特征的相关性
Oncotarget. 2017 May 26;8(43):74129-74138. doi: 10.18632/oncotarget.18273. eCollection 2017 Sep 26.
8
Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma.促甲状腺激素受体基因表达降低提示嗜酸细胞腺瘤的一个高危亚组。
Eur J Endocrinol. 2004 Mar;150(3):269-76. doi: 10.1530/eje.0.1500269.
9
Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.利用细胞学材料检测分化型甲状腺癌中促甲状腺激素受体的甲基化状态。
BMC Cancer. 2015 Oct 30;15:824. doi: 10.1186/s12885-015-1861-1.
10
Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma.BRAF基因和促甲状腺激素受体与甲状腺微小乳头状癌颈部淋巴结转移的相关性
Oncol Lett. 2019 Jan;17(1):183-194. doi: 10.3892/ol.2018.9572. Epub 2018 Oct 12.

引用本文的文献

1
TSHR in thyroid cancer: bridging biological insights to targeted strategies.甲状腺癌中的促甲状腺激素受体:将生物学见解与靶向策略相联系
Eur Thyroid J. 2025 Jul 3;14(4). doi: 10.1530/ETJ-24-0369. Print 2025 Aug 1.
2
Tailoring TSH suppression in differentiated thyroid carcinoma: evidence, controversies, and future directions.分化型甲状腺癌中促甲状腺激素抑制的个体化:证据、争议及未来方向
Endocrine. 2025 Apr 9. doi: 10.1007/s12020-025-04223-w.
3
An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.

本文引用的文献

1
Surgical Extent of Central Lymph Node Dissection for Papillary Thyroid Carcinoma Located in the Isthmus: A Propensity Scoring Matched Study.颈中部甲状腺癌行中央区淋巴结清扫术的范围:倾向评分匹配研究。
Front Endocrinol (Lausanne). 2021 Jun 15;12:620147. doi: 10.3389/fendo.2021.620147. eCollection 2021.
2
The characteristics and risk factors of central compartment lymph node metastasis in cN0 papillary thyroid carcinoma coexistent with Hashimoto's thyroiditis.合并桥本甲状腺炎的cN0期乳头状甲状腺癌中央区淋巴结转移的特征及危险因素
Gland Surg. 2020 Dec;9(6):2026-2034. doi: 10.21037/gs-20-699.
3
Low Normal TSH Levels and Thyroid Autoimmunity are Associated with an Increased Risk of Osteoporosis in Euthyroid Postmenopausal Women.
一种口服有效的促甲状腺激素受体配体可抑制甲状腺癌的生长和转移活性。
J Clin Endocrinol Metab. 2024 Aug 13;109(9):2306-2316. doi: 10.1210/clinem/dgae114.
促甲状腺激素(TSH)水平略低于正常范围及甲状腺自身免疫与甲状腺功能正常的绝经后女性骨质疏松风险增加相关。
Endocr Metab Immune Disord Drug Targets. 2021;21(5):859-865. doi: 10.2174/1871530320666200810144506.
4
Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.甲状腺乳头状癌-侵袭性变异体及其对管理的影响:叙事性综述。
Adv Ther. 2020 Jul;37(7):3112-3128. doi: 10.1007/s12325-020-01391-1. Epub 2020 Jun 1.
5
Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.促甲状腺激素受体基因甲基化与甲状腺乳头状癌的关联:一项荟萃分析。
Endocrine. 2020 Sep;69(3):508-515. doi: 10.1007/s12020-020-02284-7. Epub 2020 Apr 11.
6
Should intraoperative nerve monitoring be used routinely in primary thyroid surgeries?原发性甲状腺手术中应常规使用术中神经监测吗?
Pak J Med Sci. 2020 Jan-Feb;36(2):276-280. doi: 10.12669/pjms.36.2.1054.
7
Non Invasive Follicular Thyroid Neoplasm with Papillary like nuclear features (NIFTP), A time for change in Pakistan.具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP),巴基斯坦变革之时。
Pak J Med Sci. 2020 Jan-Feb;36(2):151-155. doi: 10.12669/pjms.36.2.1123.
8
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma.甲状腺癌浸润前沿的癌症相关成纤维细胞和衰老甲状腺细胞
Cancers (Basel). 2020 Jan 1;12(1):112. doi: 10.3390/cancers12010112.
9
Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?在首次疾病评估前,消融治疗前刺激甲状腺球蛋白 <1ng/mL 的中高危甲状腺乳头状癌患者是否仍需要 TSH 抑制治疗?
Endocrine. 2019 Jul;65(1):149-154. doi: 10.1007/s12020-019-01914-z. Epub 2019 Mar 28.
10
IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?低危和中危甲状腺乳头状癌患者在首次疾病评估前抑制 TSH 是否值得?
Endocr Pract. 2019 Feb;25(2):165-169. doi: 10.4158/EP-2018-0393. Epub 2018 Nov 1.